NCT00988364View on ClinicalTrials.gov

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Metabolic Syndrome

Interventions

DRUG

Simvastatin

Simvastatin 20mg daily for 3 months.

DRUG

Vytorin

Vytorin 20/10mg daily for 3 months.

DRUG

Placebo

Placebo one tablet daily times 3 months.

DRUG

Ezetimibe

Ezetimibe 10mg daily for 3 months.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Baylor College of Medicine

OTHER

NCT00988364 - Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. | Biotech Hunter | Biotech Hunter